Back to top

Analyst Blog

The Journal of Clinical Pharmacology recently reported population pharmacokinetic (PK) modeling and dosing simulations based on data from Hyperion Therapeutics, Inc.’s (HPTX - Snapshot Report) four phase II and phase III studies. The studies enrolled patients suffering from urea cycle disorders (UCDs) aged between 2 months and 72 years.

Hyperion described the differences in absorption rate and pharmacokinetic profiles of its two approved drugs, Ravicti and Buphenyl, in UCD patients, in the final model. Buphenyl is approved in the US for the treatment of UCD. Ravicti is approved in the US as a nitrogen-binding agent for chronic management of adult and pediatric UCD patients more than two years of age who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Data from the final model revealed that phenylbutyric acid is absorbed slowly in patients treated with Ravicti compared to those treated with Buphenyl. Moreover, patients under Ravicti also showed less fluctuation in blood metabolite levels compared to those under Buphenyl.

We remind investors that earlier this month Hyperion acquired global rights to Buphenyl tablets and powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals (VRX - Analyst Report).

Last year, Hyperion had acquired worldwide rights to Ravicti from Ucyclyd for an upfront payment of $6 million, future payments based upon the achievement of regulatory milestones in indications other than UCD, sales milestones, and mid-to-high, single-digit royalties on global net sales of Ravicti.

Hyperion currently carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. and Jazz Pharmaceuticals (JAZZ - Analyst Report) look well positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%